Business and Finance

Newly initiated trials may prove value—but even then, supplies may be limited, and hoarding is already occurring

US list-price sales reached $510 billion in 2019

Copenhagen, Denmark tops Boyd Co.’s list with the highest annual operating costs

But: the growth number of companies is exceeding the growth of trials

The big question is how well will the system respond to spikes in demand, and lack of product

PCMA study disputes its members’ harm to brick-and-mortar businesses

ICER will expand use of RWE, as the Federal ONC calls for broader use of healthcare data

Deal with Evoke Pharmaceuticals anticipates FDA approval

Too many states have opted out of the $18-billion agreement being negotiated in federal court

A former executive at PhRMA, Davis will now lead the wholesaler-distributor association

French health-products distributor EHDH will acquire the asset

Thermo Fisher to provide manufacturing expertise

ARM-sponsored study projects a 23% reduction in the cost of treating blood diseases in 2029 by administering cellular and genetic therapies

Trump administration drops its bombshell proposal to open up the US pharmaceutical market

The ‘broken promise’ of lower-cost insulin, according to Senators Warren and Blumenthal

Higher inventory turns, lower inventories—but lower profit margins, too

Change.org touts its influence in the decision

Dealing with pharma’s commercial data deluge

Licensing for Gilead’s Truvada and Descovy products is in question

Action expands Pharma Logistics’ leadership in servicing independent pharmacies

Task force report highlights the economic disincentives of short-supply products

Upstart organization seeks to create another pathway for acceptance by regulators and pharmacy benefit managers

Analysis of its members’ covered lives show the effect of expensive specialty drugs on insurance plans

Leading pharma sampling-services company ‘recapitalizes’ with acquisition by Court Square Capital

The trend line, which had been downward for nearly a decade, is turning

KPMG survey finds higher interest in M&A, but not as the top choice

Building up a service offering from the research lab to the patient’s home